Cell Therapy, Antibodies, Small Molecules

Kairos Pharma Ltd. is focused on developing innovative therapies aimed at reversing cancer drug resistance and immune suppression. One of their key products, ENV105, is an antibody designed to counteract the effects of CD105, a protein that cancer cells produce to evade treatment with anti-androgen drugs used in prostate cancer and targeted therapies for lung cancer. Currently, ENV105 is undergoing clinical trials, with Phase 2 trials for prostate cancer and Phase 1 trials for lung cancer. The company believes that since the CD105 mechanism is implicated in various cancers, ENV105 has the potential to be effective across a wide range of malignancies as they develop resistance to standard treatments.

In addition to addressing drug resistance, Kairos Pharma has developed technologies to combat immune suppression caused by cancer. KROS101 is a small molecule immunotherapy that uniquely enhances T cell proliferation and efficacy against cancer cells. Furthermore, KROS201 is a T cell therapy specifically targeting cancer stem cells, which are thought to be responsible for glioblastoma. KROS201 has received FDA clearance for an Investigational New Drug (IND) application, allowing it to proceed to clinical trials. Together, these technologies represent a significant advancement in cancer treatment, aiming to improve patient outcomes by tackling both resistance and immune evasion.

United States

Kairos Pharma is focused on developing cutting-edge therapeutics for cancer patients that reverse the inhibitory effects of cancer on the immune system. By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life.

Kairos Pharma Ltd.

Company Details